{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:16:40Z","timestamp":1785737800442,"version":"3.56.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1002\/jps.24167","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T01:50:18Z","timestamp":1410918618000},"page":"3648-3656","source":"Crossref","is-referenced-by-count":4,"title":["Developing an In Vitro Understanding of Patient Experience with Hydrofluoroalkane-Metered Dose Inhalers"],"prefix":"10.1016","volume":"103","author":[{"given":"William H.","family":"Doub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhakar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Limb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changning","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diem","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24167_bb0005","series-title":"The Montreal Protocol on substances that deplete the ozone layer as adjusted or amended in London 1990, Copenhagen 1992, Vienna 1995, Montreal 1997, Beijing 1999","author":"Sarma","year":"2000"},{"key":"10.1002\/jps.24167_bb0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1089\/jam.1995.8.Suppl_1.S-3","article-title":"CFCs, their replacements, and the ozone-layer","volume":"8","author":"Noakes","year":"1995","journal-title":"J Aerosol Med"},{"issue":"2","key":"10.1002\/jps.24167_bb0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2500\/ajra.2013.27.3857","article-title":"Therapeutic equivalence of triamcinolone acetonide hydrofluoroalkane and chlorofluorocarbon nasal inhalers in patients with seasonal allergic rhinitis","volume":"27","author":"Schenkel","year":"2013","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1002\/jps.24167_bb0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2125.2010.03857.x","article-title":"Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide","volume":"71","author":"Clearie","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1002\/jps.24167_bb0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1358\/mf.2005.27.8.928309","article-title":"Pharmacodynamic equivalence study of CFC-free and CFC-containing procaterol hydrochloride metered-dose inhalers","volume":"27","author":"Kawai","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"1","key":"10.1002\/jps.24167_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/089426803764928356","article-title":"Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects","volume":"16","author":"Joguparthi","year":"2003","journal-title":"J Aerosol Med"},{"issue":"3","key":"10.1002\/jps.24167_bb0035","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/00044011-200323030-00004","article-title":"One-year evaluation of the safety and efficacy of ipratropium bromide HFA and CFC inhalation aerosols in patients with chronic obstructive pulmonary disease","volume":"23","author":"Brazinsky","year":"2003","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1002\/jps.24167_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0091-6749(98)70186-1","article-title":"Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: A controlled trial","volume":"101","author":"Blumenthal","year":"1998","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1002\/jps.24167_bb0045","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1365-2222.2011.03820.x","article-title":"Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: A real-world observational study","volume":"41","author":"Barnes","year":"2011","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1002\/jps.24167_bb0050","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3109\/10837450.2012.680596","article-title":"Reformulation of Stmerin (R) D CFC formulation using HFA propellants","volume":"18","author":"Murata","year":"2013","journal-title":"Pharm Dev Technol"},{"key":"10.1002\/jps.24167_bb0055","unstructured":"FDA Adverse Event Reporting System (FAERS) (formerly AERS). http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatory Information\/Surveillance\/AdverseDrugEffects\/ucm082193.htm."},{"issue":"1","key":"10.1002\/jps.24167_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0378-5173(99)00133-7","article-title":"A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers","volume":"186","author":"Gabrio","year":"1999","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1002\/jps.24167_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1517\/17425247.4.3.215","article-title":"The rejuvenated pressurised metered dose inhaler","volume":"4","author":"Bell","year":"2007","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"10.1002\/jps.24167_bb0070","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000063276","article-title":"Moving from CFC aerosol to HFA aerosol or dry powder inhalers: What do patients think?","volume":"69","author":"Hartung","year":"2002","journal-title":"Respiration"},{"issue":"2, Supplement 1","key":"10.1002\/jps.24167_bb0075","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/S0091-6749(03)80473-6","article-title":"Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an aerosol via a metered dose inhaler","volume":"111","author":"Sheth","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"1\u20132","key":"10.1002\/jps.24167_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-5173(98)00237-3","article-title":"Metered-dose inhaler formulation of fluticasone-17-propionate micronized with supercritical carbon dioxide using the alternative propellant HFA-227","volume":"173","author":"Steckel","year":"1998","journal-title":"Int J Pharm"},{"issue":"s1","key":"10.1002\/jps.24167_bb0085","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1089\/jam.1995.8.Suppl_1.S-19","article-title":"The challenge of reformulation","volume":"8","author":"Smith","year":"1995","journal-title":"J Aerosol Med"},{"issue":"1","key":"10.1002\/jps.24167_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2306\/scienceasia1513-1874.2011.37.031","article-title":"Development of budesonide suspensions for use in an HFA pressurized metered dose inhaler","volume":"37","author":"Sukasame","year":"2011","journal-title":"Scienceasia"},{"issue":"3","key":"10.1002\/jps.24167_bb0095","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1208\/s12249-013-9984-7","article-title":"Evaluation of an abbreviated impactor for fine particle fraction (FPF) determination of inhalation drugs","volume":"14","author":"Guo","year":"2013","journal-title":"AAPS Pharm Sci Tech"},{"issue":"8","key":"10.1002\/jps.24167_bb0100","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/jps.21648","article-title":"Evaluation of impaction force of nasal sprays and metered-dose inhalers using the texture analyser","volume":"98","author":"Guo","year":"2009","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1002\/jps.24167_bb0105","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0169-409X(03)00079-6","article-title":"The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers","volume":"55","author":"Smyth","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1002\/jps.24167_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1378\/chest.127.1.335","article-title":"Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians\/American College of Asthma, Allergy, and Immunology","volume":"127","author":"Dolovich","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1002\/jps.24167_bb0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/jamp.2008.0739","article-title":"Quantitative analysis and design of a spray aerosol inhaler. Part 1: Effects of dilution air inlets and flow paths","volume":"22","author":"Longest","year":"2009","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"26","key":"10.1002\/jps.24167_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5260","article-title":"Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: A systematic review of the literature","volume":"5","author":"Brocklebank","year":"2001","journal-title":"Health Technol Assess"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915303282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915303282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T18:29:06Z","timestamp":1538245746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915303282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0022354915303282"],"URL":"https:\/\/doi.org\/10.1002\/jps.24167","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}